Ontruzant Kit
Product Images NDC 78206-148

9 FDA label images from Organon Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ontruzant (NDC 78206-148). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Organon Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ontruzant 01)

Figure 1 (Ontruzant 01)
A cumulative incidence graph showing the comparison over time from initiation of Paclitaxel/Trastuzumab treatment (in years) between two groups labeled AC->T and AC->T+H. The y-axis represents cumulative incidence, and the x-axis represents time in years. The graph includes shaded confidence intervals and a table of number at risk below the x-axis.*
FDA Label Image

Figure 2 (Ontruzant 02)

Figure 2 (Ontruzant 02)
A line graph depicting cumulative incidence over time from randomization (in months) up to 24 months, comparing Trastuzumab 1-Year treatment versus Observation Only. The x-axis represents time from randomization in months, and the y-axis shows cumulative incidence. The graph includes number at risk counts at specific time points for each group, with a solid line for Trastuzumab 1-Year and a dashed line for Observation Only.*
FDA Label Image

Figure 3 (Ontruzant 03)

Figure 3 (Ontruzant 03)
A line graph showing cumulative incidence of an event over time (in months) for three chemotherapy regimens: AC to T (doxorubicin and cyclophosphamide to docetaxel), AC to TH (doxorubicin and cyclophosphamide to docetaxel plus trastuzumab), and TCH (docetaxel plus carboplatin plus trastuzumab). The graph includes a legend differentiating the three regimens and a table indicating the number of patients at risk at various time points.*
FDA Label Image

Figure 4 (Ontruzant 04)

Figure 4 (Ontruzant 04)
This chart illustrates disease-free survival over 3.5 years, comparing two treatment regimens involving doxorubicin and cyclophosphamide followed by paclitaxel. One regimen includes trastuzumab (dashed line), and the other does not (solid line). The y-axis shows the proportion event-free, while the x-axis shows years of survival. Number at risk is tabulated below.*
FDA Label Image

Figure 5 (Ontruzant 05)

Figure 5 (Ontruzant 05)
A Kaplan-Meier survival curve chart depicting overall survival (years) on the x-axis and proportion alive on the y-axis. It compares two treatment groups: AC->T (doxorubicin + cyclophosphamide followed by paclitaxel) shown with a solid line and AC->T + H (same regimen plus trastuzumab) shown with a dashed line. The chart includes a risk table detailing patient numbers at various yearly intervals for both groups.*
FDA Label Image

Figure 6 (Ontruzant 06)

Figure 6 (Ontruzant 06)
A Kaplan-Meier survival curve chart showing disease-free survival over years for three chemotherapy regimens: AC followed by TH, AC followed by TCH, and AC followed by T. The x-axis represents disease-free survival in years (0 to 5), and the y-axis shows proportion event-free (0 to 1). A legend identifies the regimens, with the number of patients at risk listed below the x-axis. The chart compares survival proportions across the treatments over time.*
FDA Label Image

Chemical Structure (Ontruzant 07)

Chemical Structure (Ontruzant 07)
A survival probability chart showing product-limit survival estimates over a duration of up to 50 months. The chart compares two treatment groups: Fluoropyrimidine + Cisplatin and Fluoropyrimidine + Cisplatin + Trastuzumab. The x-axis represents duration of survival in months, and the y-axis represents survival probability, with censored data marked. Number of subjects at risk is shown at intervals along the timeline.*
FDA Label Image

Principal Display Panel (150 mg Vial Carton)

Principal Display Panel (150 mg Vial Carton)
Ontruzant 150 mg/vial kit packaging label for intravenous injection by Organon LLC. The label includes the product name, strength, dosage form, reconstitution instructions, storage requirements, manufacturer details (Samsung Bioepis Co., Ltd., Korea), and barcode. It specifies that Ontruzant is for intravenous infusion only and must be reconstituted and diluted before use.*
FDA Label Image

Principal Display Panel (Kit Vial Carton)

Principal Display Panel (Kit Vial Carton)
Ontruzant 420 mg vial kit packaging label for intravenous injection, containing trastuzumab-dttb. The label states it is a multiple-dose vial distributed by Organon LLC and manufactured by Samsung Bioepis Co., Ltd. Instructions include refrigeration requirements, reconstitution, and dilution for infusion, with storage and handling details. The carton includes one 420 mg vial and one vial of bacteriostatic water for injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.